As recommended previously [2], [3], the favorable outcome subgroup (n = 23) are those CN-AML patients who have the NPM1 gene mutation (NPM1mt) but do not have the internal tandem duplication in the FLT3 gene (FLT3ITD). This evidence concerns the gene FLT3 and acute myeloid leukemia.